Combination of intratumoural micellar paclitaxel with radiofrequency ablation: efficacy and toxicity in rodents
- 21 Downloads
To determine whether radiofrequency ablation (RFA) is more effective when combined with intratumoural injection (IT) than with intravenous injection (IV) of micelles.
Materials and methods
Balb/c mice bearing 4T1 breast cancer were used. The tumour drug accumulation and biodistribution in major organs were evaluated at different time points after IT, IV, IT+RFA and IV+RFA. Periablational drug penetration was evaluated by quantitative analysis and pathologic staining after different treatments. For long-term outcomes, mice bearing tumours were randomised into six groups (n = 7/group): the control, IV, IT, RFA alone, IV+RFA and IT+RFA groups. The end-point survival was estimated for the different treatment groups.
In vivo, intratumoural drug accumulation was always much higher for IT than for IV within 48 h (p < 0.001). The IT+RFA group (3084.7 ± 985.5 μm) exhibited greater and deeper drug penetration than the IV+RFA group (686.3 ± 83.7 μm, p < 0.001). Quantitatively, the intratumoural drug accumulation in the IT+RFA group increased approximately 4.0-fold compared with that in the IV+RFA group (p < 0.001). In addition, compared with the IT treatment, the IT+RFA treatment further reduced the drug deposition in the main organs. Survival was longer in the IT+RFA group than in the IV+RFA (p = 0.033) and RF alone (p = 0.003) groups.
The use of IT+RFA achieved much deeper and greater intratumoural drug penetration and accumulation, resulting in better efficacy, and decreased the systemic toxicity of nanoparticle-delivered chemotherapy.
• Association of IT+RFA achieved much deeper and greater intratumoural drug penetration than of IV+RFA, leading to better therapeutic efficacy.
• Compared with IV or IT chemotherapy alone, the combination with RFA decreased toxicity, especially in the IT+RFA group.
KeywordsMice, inbred Babl/c Micelles Injections, intravenous Injections, intralesional Radiofrequency ablation
This study has received funding by the National Natural Science Foundation of China (Grant Nos. 81471768, 81773286, 81571674 and 81771853).
Compliance with ethical standards
The scientific guarantor of this publication is Yang Wei.
Conflict of interest
One author (S.N.G.) receives consulting fees from Angiodynamics and Cosman Company. These companies had no control or involvement in data collection, data analysis, or manuscript preparation. Other authors had no conflict of interest and had unrestricted control of study data.
Statistics and biometry
Goldberg SN, Ahmed Muneeb and Zhang Qiang kindly provided statistical and constructive advice for this manuscript.
Approval from the institutional animal care committee was obtained.
Institutional Review Board approval was obtained.
• Performed at one institution
- 1.Ahmed M, Brace CL, Lee FT Jr, Goldberg SN (2011) Principles of and advances in percutaneous ablation. Radiology 258:351–369Google Scholar
- 3.Ni JY, Liu SS, Xu LF, Sun HL, Chen YT (2013) Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 19:3872–3882Google Scholar
- 8.Ahmed M, Monsky WE, Girnun G et al (2003) Radiofrequency thermal ablation sharply increases intratumoral liposomal doxorubicin accumulation and tumor coagulation. Cancer Res 63:6327–6333Google Scholar
- 16.Xie H, Goins B, Bao A, Wang ZJ, Phillips WT (2012) Effect of intratumoral administration on biodistribution of 64Cu-labeled nanoshells. Int J Nanomedicine 7:2227–2238Google Scholar
- 18.Heldin CH, Rubin K, Pietras K, Ostman A (2004) High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 4:806–813Google Scholar
- 20.Lund T, Wiig H, Reed RK (1988) Acute postburn edema: role of strongly negative interstitial fluid pressure. Am J Physiol 255:H1069–H1074Google Scholar
- 24.Kruskal JB, Oliver B, Huertas JC, Goldberg SN (2001) Dynamic intrahepatic flow and cellular alterations during radiofrequency ablation of liver tissue in mice. J Vasc Interv Radiol 12:1193–1201Google Scholar
- 25.Kong G, Anyarambhatla G, Petros WP et al (2000) Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 60:6950–6957Google Scholar
- 26.Grüll H, Langereis S (2012) Hyperthermia-triggered drug delivery from temperature-sensitive liposomes using MRI-guided high intensity focused ultrasound. J Control Release 161:317–327Google Scholar
- 28.Ning S, Yu N, Brown DM, Kanekal S, Knox SJ (1999) Radiosensitization by intratumoral administration of cisplatin in a sustained-release drug delivery system. Radiother Oncol 50:215–223Google Scholar
- 30.Santagiuliana R, Pereira RC, Schrefler BA, Decuzzi P (2018) Predicting the role of microstructural and biomechanical cues in tumor growth and spreading. Int J Numer Method Biomed Eng 34:e2935Google Scholar
- 31.Rajabi M, Mousa SA (2017) The role of angiogenesis in cancer treatment. Biomedicines 5:34Google Scholar